Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)

Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome–positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common “gatekeeper” mutation T315I. Here we investigated the therapeutic poten...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Ann Hematol
Main Authors: Mian, Afsar Ali, Haberbosch, Isabella, Khamaisie, Hazem, Agbarya, Abed, Pietsch, Larissa, Eshel, Elizabeh, Najib, Dally, Chiriches, Claudia, Ottmann, Oliver Gerhard, Hantschel, Oliver, Biondi, Ricardo M., Ruthardt, Martin, Mahajna, Jamal
Format: Artigo
Sprog:Inglês
Udgivet: Springer Berlin Heidelberg 2021
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8285356/
https://ncbi.nlm.nih.gov/pubmed/34110462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-020-04357-z
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker